Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering

Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing cancer therapy due to their established safety in allogeneic contexts and inherent tumor-fighting capabilities. Nonetheless, the limited clinical success of Vδ2 T cell-based treatments may be attributed to donor var...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Derek, Dunn, Zachary Spencer, Guo, Wenbin, Rosenthal, Carl J., Penn, Natalie E., Yu, Yanqi, Zhou, Kuangyi, Li, Zhe, Ma, Feiyang, Li, Miao, Song, Tsun-Ching, Cen, Xinjian, Li, Yan-Ruide, Zhou, Jin J., Pellegrini, Matteo, Wang, Pin, Yang, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632431/
https://www.ncbi.nlm.nih.gov/pubmed/37938576
http://dx.doi.org/10.1038/s41467-023-42619-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632431/
https://www.ncbi.nlm.nih.gov/pubmed/37938576
http://dx.doi.org/10.1038/s41467-023-42619-2

Ejemplares similares